GE’s Triple Threat Breakup

General Electric‘s removal from the Dow Jones Industrial Average in June 2018 marked a dramatic conclusion to an original participant’s multi-decade decline. Since GE was sidelined from the exclusive index, a lot has happened — but a lot more is still left to be accomplished to undo decades of mishaps. 

The company’s new CEO, Larry Culp, hopes to right the wrongs of GE’s past, present, and future. However, its wrongs have turned into a mountain of debt. GE has been selling assets to cover it, but Culp and company have a new pitch for investors: splitting up GE.

The one-time industrial giant will be broken up into three companies: one for aviation, another for healthcare, and the final for its power business. ✈️  ⚕️ ⚡ The three companies will be separate, publicly-traded companies. According to Culp, “this is the best way to fully realize the potential of these businesses.”

The changes will take time, though. GE Healthcare, which makes MRIs and hospital equipment, will spin off in 2023. The unit did $17 billion in revenue in 2020. In 2024, it will spin off its power & renewable energy unit — that includes all of its turbines for power plants, wind farms, and other stuff along those lines. That unit did an even more impressive $33 billion in revenue in 2020.

What’s left behind under the original ticker will be a very different $GE than the diversified disaster that exists today. GE will focus on aviation, namely making and servicing jet engines. That business did $22 billion in revenue in 2020, despite the pandemic.

$GE rose 2.7% on the news today, an indication that investors are liking the reorganization. 👍

DWAC Bounces Back (Again)

We mentioned last week that investors were preparing for a politically driven 2024, and boy, that accelerated quickly. 😜

Trump-linked stocks Digital World Acquisition Corp, Phunware, and Rumble jumped sharply today after Ron DeSantis canceled his presidential run.

Read It

Biotech Buyout Spree Continues

It may be the last week of the year, but many companies are rushing to get deals done before year-end. Two significant transactions in the biotech space were announced today, so let’s dive in. 👇

The first deal involves RayzeBio, which raised $358 million via an initial public offering (IPO) just three months ago. However, its time as a public company is being cut short by Bristol Myers Squibb, which is acquiring the radiopharmaceutical therapeutics company for $62.50 per share in cash. 💰

Read It

Japan’s Nippon Takes Over U.S. Steel

After months of bidding, U.S. Steel finally has a buyer. However, the auction’s winner has some parties concerned. 🤔

Japan’s Nippon Steel emerged as the top bidder for the 122-year-old steelmaker, beating out offers from Cleveland-Cliffs, ArcelorMittal, and Nucor. Its $55 per share price represents a 142% premium to where $X shares were trading before Cleveland-Cliffs’ $35-per-share offer kicked off the bidding war.

Read It

PayPal Pops Ahead Of Key Event

It’s been a rough few years for payment giant PayPal, with shares falling 85% peak-to-trough. Recently, the stock has begun to rebound with other beaten-down tech names but remains about 80% below all-time highs. In other words, it would need to nearly 5x its share price to reach those levels again. 📈

While that may seem a ways off, investors have recently pushed shares to their best three-day run since the end of 2022. That’s because the company promised to roll out new “customer-backed innovation” at an event next Thursday, with its new CEO Alex Chriss saying, “It is very clear what we need to do.”

Read It